Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts

Nora Franceschini, Orlena Cheng, Xiaojie Zhang, Phillip Ruiz, Roslyn B. Mannon

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Interstitial fibrosis, glomerulosclerosis and arteriosclerosis are the major components of chronic allograft nephropathy (CAN), the leading cause of late graft failure after transplantation. To investigate the mechanism of collagen deposition in CAN, we studied the effects of prolyl-hydroxylase inhibitor (PHI), an enzyme essential for collagen formation, using a mouse model of kidney transplantation. Kidneys from H-2b mice were transplanted into MHC-incompatible H-2d recipients (allografts) and at 3 weeks posttransplant, received either PHI or vehicle treatment daily for 3 weeks. At 6 weeks post-transplant, GFR was significantly improved in the allografts receiving PHI (3.3±0.5 mL/min/kg) compared with those receiving vehicle (1.8±0.5 mL/min/kg, p<0.05), while renal function was relatively unimpaired in the nonrejecting isografts (6.45±0.53 mL/min/kg). Allografts had histologic changes of CAN but the severity was significantly reduced with PHI treatment compared with vehicle, with reductions in interstitial inflammation and fibrosis. Furthermore, TGFâ and connective tissue growth factor mRNA expression was enhanced in both allograft groups compared with the isografts. In conclusion, PHI-treated allografts had improved renal function and reduced the severity of renal injury as a result of CAN. Inhibition of matrix synthesis may be a useful adjunct in ameliorating the development of CAN in humans.

Original languageEnglish
Pages (from-to)396-402
Number of pages7
JournalAmerican Journal of Transplantation
Volume3
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

Prolyl Hydroxylases
Allografts
Prolyl-Hydroxylase Inhibitors
Kidney
Isografts
Fibrosis
Collagen
Connective Tissue Growth Factor
Transplants
Arteriosclerosis
Kidney Transplantation
Transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. / Franceschini, Nora; Cheng, Orlena; Zhang, Xiaojie; Ruiz, Phillip; Mannon, Roslyn B.

In: American Journal of Transplantation, Vol. 3, No. 4, 01.04.2003, p. 396-402.

Research output: Contribution to journalArticle

Franceschini, Nora ; Cheng, Orlena ; Zhang, Xiaojie ; Ruiz, Phillip ; Mannon, Roslyn B. / Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. In: American Journal of Transplantation. 2003 ; Vol. 3, No. 4. pp. 396-402.
@article{1376bd0e8fd143b58f2b71f82e5760c0,
title = "Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts",
abstract = "Interstitial fibrosis, glomerulosclerosis and arteriosclerosis are the major components of chronic allograft nephropathy (CAN), the leading cause of late graft failure after transplantation. To investigate the mechanism of collagen deposition in CAN, we studied the effects of prolyl-hydroxylase inhibitor (PHI), an enzyme essential for collagen formation, using a mouse model of kidney transplantation. Kidneys from H-2b mice were transplanted into MHC-incompatible H-2d recipients (allografts) and at 3 weeks posttransplant, received either PHI or vehicle treatment daily for 3 weeks. At 6 weeks post-transplant, GFR was significantly improved in the allografts receiving PHI (3.3±0.5 mL/min/kg) compared with those receiving vehicle (1.8±0.5 mL/min/kg, p<0.05), while renal function was relatively unimpaired in the nonrejecting isografts (6.45±0.53 mL/min/kg). Allografts had histologic changes of CAN but the severity was significantly reduced with PHI treatment compared with vehicle, with reductions in interstitial inflammation and fibrosis. Furthermore, TGF{\^a} and connective tissue growth factor mRNA expression was enhanced in both allograft groups compared with the isografts. In conclusion, PHI-treated allografts had improved renal function and reduced the severity of renal injury as a result of CAN. Inhibition of matrix synthesis may be a useful adjunct in ameliorating the development of CAN in humans.",
author = "Nora Franceschini and Orlena Cheng and Xiaojie Zhang and Phillip Ruiz and Mannon, {Roslyn B.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1034/j.1600-6143.2003.00081.x",
language = "English",
volume = "3",
pages = "396--402",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts

AU - Franceschini, Nora

AU - Cheng, Orlena

AU - Zhang, Xiaojie

AU - Ruiz, Phillip

AU - Mannon, Roslyn B.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Interstitial fibrosis, glomerulosclerosis and arteriosclerosis are the major components of chronic allograft nephropathy (CAN), the leading cause of late graft failure after transplantation. To investigate the mechanism of collagen deposition in CAN, we studied the effects of prolyl-hydroxylase inhibitor (PHI), an enzyme essential for collagen formation, using a mouse model of kidney transplantation. Kidneys from H-2b mice were transplanted into MHC-incompatible H-2d recipients (allografts) and at 3 weeks posttransplant, received either PHI or vehicle treatment daily for 3 weeks. At 6 weeks post-transplant, GFR was significantly improved in the allografts receiving PHI (3.3±0.5 mL/min/kg) compared with those receiving vehicle (1.8±0.5 mL/min/kg, p<0.05), while renal function was relatively unimpaired in the nonrejecting isografts (6.45±0.53 mL/min/kg). Allografts had histologic changes of CAN but the severity was significantly reduced with PHI treatment compared with vehicle, with reductions in interstitial inflammation and fibrosis. Furthermore, TGFâ and connective tissue growth factor mRNA expression was enhanced in both allograft groups compared with the isografts. In conclusion, PHI-treated allografts had improved renal function and reduced the severity of renal injury as a result of CAN. Inhibition of matrix synthesis may be a useful adjunct in ameliorating the development of CAN in humans.

AB - Interstitial fibrosis, glomerulosclerosis and arteriosclerosis are the major components of chronic allograft nephropathy (CAN), the leading cause of late graft failure after transplantation. To investigate the mechanism of collagen deposition in CAN, we studied the effects of prolyl-hydroxylase inhibitor (PHI), an enzyme essential for collagen formation, using a mouse model of kidney transplantation. Kidneys from H-2b mice were transplanted into MHC-incompatible H-2d recipients (allografts) and at 3 weeks posttransplant, received either PHI or vehicle treatment daily for 3 weeks. At 6 weeks post-transplant, GFR was significantly improved in the allografts receiving PHI (3.3±0.5 mL/min/kg) compared with those receiving vehicle (1.8±0.5 mL/min/kg, p<0.05), while renal function was relatively unimpaired in the nonrejecting isografts (6.45±0.53 mL/min/kg). Allografts had histologic changes of CAN but the severity was significantly reduced with PHI treatment compared with vehicle, with reductions in interstitial inflammation and fibrosis. Furthermore, TGFâ and connective tissue growth factor mRNA expression was enhanced in both allograft groups compared with the isografts. In conclusion, PHI-treated allografts had improved renal function and reduced the severity of renal injury as a result of CAN. Inhibition of matrix synthesis may be a useful adjunct in ameliorating the development of CAN in humans.

UR - http://www.scopus.com/inward/record.url?scp=0037652301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037652301&partnerID=8YFLogxK

U2 - 10.1034/j.1600-6143.2003.00081.x

DO - 10.1034/j.1600-6143.2003.00081.x

M3 - Article

C2 - 12694061

AN - SCOPUS:0037652301

VL - 3

SP - 396

EP - 402

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 4

ER -